Search Results - N. L. Kozlovskaya
-
1
Prospects for the use of belimumab in lupus nephritis
Published 2021-08-01Get full textOver the past 50 years the survival rate of patients with systemic lupus erythematosus (SLE) significantly improved, however, it is necessary to develop a new generation of drugs for the treatment of lupus nephritis (LN), the development of which is one of the main factors of high mortality risk in...
Article -
2
PROGNOSTIC IMPACT OF COMMUNITY-ACQUIRED AND HOSPITAL-ACQUIRED HYPONATREMIA IN PATIENTS WITH DECOMPENSATED HEART FAILURE
Published 2015-09-01Get full textAim. To compare prognostic impact of community-acquired and hospital-acquired hyponatremia in hospitalized patients with decompensated heart failure Material and methods. Data of 120 patients with decompensated heart failure were analyzed. Hyponatremia was defined as serum sodium concentration of 13...
Article -
3
Features of Ocular Blood Flow in Malignant Arterial Hypertension of Renal Origin
Published 2023-07-01Get full textColor Doppler imaging allows a detailed non-invasive assessment of the state of blood flow in the retrobulbar vessels in patients with various vascular pathologies. Malignant hypertension (MH) is a clinical syndrome characterized by severe diastolic arterial hypertension (140 mm Hg or more), leading...
Article -
4
Lupus nephritis – modern aspects of diagnosis and therapy. Part I
Published 2024-03-01Get full textLupus nephritis (LN) is considered to be one of the most frequent severe manifestations of systemic lupus erythematosus (SLE), its various colonic manifestations occur in at least 50% of SLE patients, both at the onset and at various stages of the disease, and develop LN is considered one of the mos...
Article -
5
Difficulties of biological therapy in the patient with active rheumatoid arthritis and secondary renal amyloidosis: A report of clinical case
Published 2021-05-01Get full textA clinical case of a patient with active rheumatoid arthritis (RA) resistant to standard basic therapy is presented, which served as the reason for the appointment of the target drug – Janus kinase, tofacitinib (Jaquinus) and then biological therapy using anti-IL6 receptor antibody tocilizumab (Acte...
Article -
6
The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I
Published 2020-11-01Get full textThe paper presents the main provisions of the 2019 updated European League Against Rheumatism (EULAR)/European Renal Association (ERA) – European Dialysis and Transplant Association (EDTA) guidelines for the management of lupus nephritis. It discusses the technology of preparing recommendations by a...
Article -
7
The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II
Published 2021-02-01Get full textThe paper presents the main provisions of the updated 2019 EULAR/ERA-EDTA guidelines for the lupus nephritis (LN) therapy, which have been prepared by an international group of rheumatologists, nephrologists, morphologists, and pediatricians. Part 2 of the article discusses additional therapy, monit...
Article